These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32296041)

  • 41. Cord blood stem cell derived CD16
    Valipour B; Abedelahi A; Naderali E; Velaei K; Movassaghpour A; Talebi M; Montazersaheb S; Karimipour M; Darabi M; Chavoshi H; Nozad Charoudeh H
    Life Sci; 2020 Feb; 242():117223. PubMed ID: 31881222
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of PD-L1 in EBV-associated malignancies.
    Li X; Zhang W
    Int Immunopharmacol; 2021 Jun; 95():107553. PubMed ID: 33765613
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A fully human anti-CD47 blocking antibody with therapeutic potential for cancer.
    Zeng D; Sun Q; Chen A; Fan J; Yang X; Xu L; Du P; Qiu W; Zhang W; Wang S; Sun Z
    Oncotarget; 2016 Dec; 7(50):83040-83050. PubMed ID: 27863402
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthetic CD47 antibody-chitosan/hyaluronic acid polyelectrolyte complex mediates targeted inhibition of atherosclerotic plaques by exogenous foam-like cells via the NLRP3 pathway.
    Yu J; Ruan Q; Nie X; Yu L; Huang B
    J Biomater Appl; 2020 May; 34(10):1381-1394. PubMed ID: 32063073
    [No Abstract]   [Full Text] [Related]  

  • 45. Therapeutic intervention in cancer and chronic viral infections: antibody mediated manipulation of PD-1/PD-L1 interaction.
    Sakthivel P; Gereke M; Bruder D
    Rev Recent Clin Trials; 2012 Feb; 7(1):10-23. PubMed ID: 22023178
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.
    Xu M; Han Y; Liu G; Xu Y; Duan D; Liu H; Du F; Luo P; Liu Z
    Mol Pharm; 2018 Oct; 15(10):4426-4433. PubMed ID: 30133286
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential.
    Ma L; Zhu M; Gai J; Li G; Chang Q; Qiao P; Cao L; Chen W; Zhang S; Wan Y
    J Nanobiotechnology; 2020 Jan; 18(1):12. PubMed ID: 31931812
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CD47 blockade as another immune checkpoint therapy for cancer.
    Vonderheide RH
    Nat Med; 2015 Oct; 21(10):1122-3. PubMed ID: 26444633
    [No Abstract]   [Full Text] [Related]  

  • 49. Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model.
    Tao H; Qian P; Wang F; Yu H; Guo Y
    Oncol Res; 2017 Nov; 25(9):1579-1587. PubMed ID: 28337964
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
    Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
    Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells.
    Miyazaki T; Ishikawa E; Matsuda M; Sugii N; Kohzuki H; Akutsu H; Sakamoto N; Takano S; Matsumura A
    Brain Tumor Pathol; 2020 Apr; 37(2):41-49. PubMed ID: 31980975
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity.
    de Silva S; Fromm G; Shuptrine CW; Johannes K; Patel A; Yoo KJ; Huang K; Schreiber TH
    Cancer Immunol Res; 2020 Feb; 8(2):230-245. PubMed ID: 31852716
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Finding the Right Heavy Chains for Immunostimulatory Antibodies.
    Boulard P; Gouilleux-Gruart V; Watier H
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142278
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.
    Zak KM; Grudnik P; Magiera K; Dömling A; Dubin G; Holak TA
    Structure; 2017 Aug; 25(8):1163-1174. PubMed ID: 28768162
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy.
    Zhou X; Jiao L; Qian Y; Dong Q; Sun Y; Zheng WV; Zhao W; Zhai W; Qiu L; Wu Y; Wang H; Gao Y; Chen J
    Biomolecules; 2021 May; 11(5):. PubMed ID: 34068552
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
    Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
    Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a
    Ren J; Xu M; Chen J; Ding J; Wang P; Huo L; Li F; Liu Z
    Theranostics; 2021; 11(1):304-315. PubMed ID: 33391476
    [No Abstract]   [Full Text] [Related]  

  • 58. Re: Endoscopic Molecular Imaging of Human Bladder Cancer Using a CD47 Antibody.
    Chang SS
    J Urol; 2016 Apr; 195(4 Pt 1):1170. PubMed ID: 27302826
    [No Abstract]   [Full Text] [Related]  

  • 59. Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1.
    Nemoto Y; Shosu K; Okuda M; Noguchi S; Mizuno T
    Vet Immunol Immunopathol; 2018 Apr; 198():19-25. PubMed ID: 29571514
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CD47 checkpoint data supercharge Stanford spinout IPO.
    Dolgin E
    Nat Biotechnol; 2018 Aug; 36(8):671-672. PubMed ID: 30080839
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.